Prostatilen
Hormonal / ProstateAlso known as: Samprost, Vitaprost, Простатилен, Prostate Extract, Bovine Prostate Peptides
Mechanism
Prostatilen is a pharmaceutical-grade peptide extract from bovine prostate tissue, approved in Russia for the treatment of chronic prostatitis and benign prostatic hyperplasia (BPH). It reduces prostate inflammation, swelling, and pain while improving urinary flow and sexual function. Available as both injectable and suppository formulations, it is one of the most commercially successful Khavinson-derived products. Russian clinical data shows significant improvement in prostate symptoms and quality of life scores.
Technical detail
Prostatilen is a lyophilized polypeptide complex (<10 kDa) extracted from bovine prostate glands. Contains tissue-specific peptides with affinity for prostatic epithelial and stromal cells. Mechanisms: (1) Anti-inflammatory — reduces leukocyte infiltration, suppresses IL-8, TNF-α, and COX-2 expression in prostatic tissue; (2) Anti-edematous — normalizes vascular permeability in prostate microvasculature, reducing glandular swelling; (3) Antimicrobial — enhances local immune defense by stimulating secretory IgA and lysozyme production in prostatic secretions; (4) Antithrombotic — prevents microthrombosis in prostatic vasculature, improving glandular blood flow; (5) Smooth muscle modulation — normalizes detrusor/sphincter coordination for improved urinary flow. Russian clinical data: significant improvement in NIH-CPSI scores (pain, urinary, quality of life domains) in chronic prostatitis. Marketed as Prostatilen (IM injection), Vitaprost (suppository/tablet), and Samprost. Extensive post-marketing data in Russia.